Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03311334

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients With Advanced Solid Tumors

Sponsor: Sumitomo Pharma America, Inc.

Conditions Fallopian Tube Cancer Platinum-resistant Ovarian Cancer (PROC) Primary Peritoneal Cancer Renal Cell Carcinoma (RCC) Serous Epithelial Ovarian Cancer Urothelial Carcinoma

Interventions DSP-7888 Dosing Emulsion Nivolumab Pembrolizumab

Updated 20 times since 2017 Last updated: Mar 25, 2024 Started: Dec 14, 2017 Primary completion: Oct 19, 2022 Completion: Nov 29, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor's decision to terminate development of the program.

Other terminated trials from Sumitomo Pharma America, Inc.

More terminations from Sumitomo Pharma America, Inc.

Other Fallopian Tube Cancer trials with similar outcome

Browse all Fallopian Tube Cancer trials

This PHASE1/PHASE2 trial investigates Fallopian Tube Cancer and Platinum-resistant Ovarian Cancer (PROC) and is currently terminated or withdrawn. Sumitomo Pharma America, Inc. leads this study, which shows 20 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

20 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2024 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2

Status: Completed → Terminated
Nov 2023 — May 2024 [monthly]

Completed PHASE1_PHASE2

▶ Show 15 earlier versions

Jan 2023 — Nov 2023 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed
Dec 2022 — Jan 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
May 2022 — Dec 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Apr 2022 — May 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Oct 2021 — Apr 2022 [monthly]

Recruiting PHASE1_PHASE2
Apr 2021 — Oct 2021 [monthly]

Recruiting PHASE1_PHASE2
Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE1_PHASE2
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2
Aug 2020 — Dec 2020 [monthly]

Recruiting PHASE1_PHASE2
Feb 2020 — Aug 2020 [monthly]

Recruiting PHASE1_PHASE2
Sep 2019 — Feb 2020 [monthly]

Recruiting PHASE1_PHASE2

Phase: PHASE1 → PHASE1_PHASE2
Oct 2018 — Sep 2019 [monthly]

Recruiting PHASE1
Jun 2018 — Oct 2018 [monthly]

Recruiting PHASE1
Jan 2018 — Jun 2018 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Nov 2017 — Jan 2018 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sumitomo Pharma America, Inc.

Data source: Sumitomo Pharma America, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Billings, United States , Cincinnati, United States , Columbus, United States , Dallas, United States , Decatur, United States , Germantown, United States , Houston, United States , Lafayette, United States , Los Angeles, United States and 8 more locations